Clinical Trial Update: Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 [Phase 2]

View source ↗

Summary

MITO VULVA-01 is a Phase 2 clinical trial evaluating pembrolizumab plus lenvatinib in vulvar cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Vulva Cancer | Phase 2 | Status: RECRUITING